- CA$39.97m
- CA$38.84m
- CA$28.86m
Brief: Medicure Announces Direct To Patient Online Pharmacy Program For Distribution Of Zypitamag Tablets
Brief: Medicure Announces Top Line Data From Fabolus-Faster Trial With Aggrastat® Will Be Presented At The Pcr E-Course, Late Breaking Trial Sessions, June 27, 2020
Brief: Medicure Reports Quarterly Loss Per Share Of C$0.14
Brief: Medicure Reports Financial Results For Quarter And Year Ended Dec 31, 2019
Brief: Medicure Announces Completion Of Enrollment For Fabolus-Faster, Phase 4 Clinical Trial Of Aggrastat Injection vs. Kengreal
Brief: Medicure Announces Settlement Of Holdback Dispute From Apicore Sale
Brief: Medicure Files Patent Infringement Action
Brief: Medicure Reports Qtrly Net Loss $0.04 Per Share
Brief: Medicure Announces Intention To Commence Substantial Issuer Bid
Brief: Medicure Announces Preferred Pricing Agreement For Zypitamag With The AIDS Drug Assistance Program Crisis Task Force
Brief: Medicure Announces Settlement Of Patent Infringement Action
Brief: Medicure Announces Settlement Of Patent Infringement Action
Brief: Medicure Reports Financial Results For Quarter Ended June 30, 2019
Brief: Medicure Announces Renewal Of Its Normal Course Issuer Bid
Brief: Medicure Quarterly Loss Per Share C$0.18
Brief: Medicure Reports Qtrly Earnings Per Share $0.10
Brief: Medicure Says Entered Into Agreement With Sensible Medical Innovations
Brief: Medicure Reports Financial Results For Quarter Ended Sept. 30, 2018
Brief: Medicure Files Patent Infringement Action